News

October 27, 2020October 27, 2020

Pilot Study Grants Available for Ovarian Cancer Research

News

Under its Pilot Study Awards program, the Rivkin Center is funding innovative research projects that seek to expand current knowledge about ovarian cancer, the non-profit has announced. Awarded grants ... Read more

October 22, 2020October 22, 2020

FDA Places PC14586, for Cancers with Mutant Protein, on Fast Track

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to PC14586 as a potential treatment of advanced cancers that harbor a specific mutation affecting the protein ... Read more

October 20, 2020October 20, 2020

Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens

News

Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead candidate, SL-172154, in treating people with advanced ovarian cancer, the company announced in a press release. The ... Read more

October 15, 2020October 15, 2020

First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC

News

The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the ... Read more

October 13, 2020October 13, 2020

OCRA Partners With Microsoft AI Initiative to Accelerate Ovarian Cancer Research

News

The Ovarian Cancer Research Alliance (OCRA) has partnered with Microsoft‘s AI for Health initiative, with the ultimate goal of accelerating ovarian cancer research using data science and artificial intelligence ... Read more

October 8, 2020October 8, 2020

Lab-Grown 3D Tumor Model Provides New Tool to Study Ovarian Cancer, Treatments

News

A lab-grown, three-dimensional (3D) ovarian tumor model will give researchers a new way to study tumor growth in ovarian cancer and to test how tumors might respond to treatments, ... Read more

October 6, 2020October 6, 2020

Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show

News

When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs ... Read more

October 1, 2020October 1, 2020

Fertility-sparing Surgery Can Effectively Treat Borderline Ovarian Tumors, Study Shows

News

Fertility-sparing surgery can effectively treat borderline ovarian tumors (BOTs), while preserving a woman’s ability to conceive and bear children, a new study suggests. The study, “Reproductive and obstetrical outcomes ... Read more

September 29, 2020September 29, 2020

STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer

News

Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients ... Read more

September 24, 2020September 24, 2020

Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer

News

Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and ... Read more